Business
Auven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 Confirmatory Trial of KIACTA(TM) for the Treatment of Orphan Disease AA Amyloidosis
Auven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 Confirmatory T...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nAuven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 Confirmatory Trial of KIACTA™ for the Treatment of Orphan Disease AA Amyloidosis\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nAuven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 Confirmatory Trial of KIACTA™ for the Treatment of Orphan Disease AA Amyloidosis\nCanada NewsWire\nST. THOMAS, U.S. VIRGIN ISLANDS; LAUSANNE, SWITZERLAND; MADISON, NEW JERSEY; HAMILTON, BERMUDA; and, Jan. 21, 2016\n\n\n\nStudy reached 120 qualifying events, top-line results expected in Q2 2016\n\n\n\nST. THOMAS, U.S. VIRGIN ISLANDS; LAUSANNE, SWITZERLAND; MADISON, NEW JERSEY; HAMILTON, BERMUDA; and LAVAL, CANADA, Jan. 21, 2016 /CNW/ - Auven Therapeutics, a global private equity company focused on accelerated development of breakthrough therapeutic drugs, and BELLUS Health Inc. (TSX: BLU), a drug development company focused on rare diseases, today announced the completion of the KIACTA™ (eprodisate) Phase 3 confirmatory study for the treatment of AA amyloidosis. Top-line results are expected to be announced in Q2 2016 after all remaining patients have completed final study visits, all queries have been resolved based on input from study sites and the database has been locked. \n\nAA amyloidosis is a rare disease secondary to severe chronic inflammation or infection leading to the formation and deposition of amyloid fibrils in organs, often resulting in end-stage renal disease and death. Currently there are no therapies available that target the disease directly. In prior clinical studies, KIACTA™ has been shown to slow the decline of renal function in AA amyloidosis patients by its ability to interfere with the formation of amyloid fibrils A and the deposition of these fibrils in tissues.\n\n\"We designed this trial to confirm the results of the prior Phase 2/3 study in which KIACTA™ demonstrated significant delays in AA amyloidosis disease progression, in some cases for a number of years,\" said Dr. Peter B. Corr, Co-Fou...